Menu

In Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc. (March 7, 2008), the Federal Circuit reversed a decision of the U.S. District Court for the District of New Jersey holding that claims 1-4 and 11-17 of U.S. Patent No. 5,760,068 (“the ‘068 patent”) were not invalid for obviousness-type double patenting.